Trial Profile
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2017
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 24 May 2017 Status changed from recruting to discontinued accordng to results presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 08 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.